点击此处阅读调查报告全文
Our fourth annual report on Hong Kong-listed biotech companies examines how the sector performed during the continuing challenging market conditions of the last full calendar year. Although the number of...more
点击此处阅读调查报告全文
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing...more
4/25/2023
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
Corporate Governance ,
Foreign Corporations ,
Healthcare ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Life Sciences ,
Listing Rules ,
Popular ,
Publicly-Traded Companies
Our second annual report on Hong Kong-listed biotech companies demonstrates the continued health of the sector. The report provides a comprehensive overview of the market in its current state, examining key data points for...more
On February 23, 2018, the Stock Exchange of Hong Kong Limited (HKEX) published its consultation conclusions regarding a new chapter of its listing rules to facilitate the listings of pre-revenue biotech companies in Hong...more
Despite the impact of COVID-19 and other recent developments in Hong Kong, the city’s role as a center for China-based companies to raise capital became even more important in 2020. The momentum of several trends that began...more
1/29/2021
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
China ,
Foreign Relations ,
HKEx ,
Hong Kong ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
PCAOB ,
Publicly-Traded Companies ,
Securities and Exchange Commission (SEC)
This update provides an overview of key regulatory developments in the past three months relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In particular,...more
7/14/2020
/ Acquisitions ,
Amended Rules ,
Biotechnology ,
Board of Directors ,
Censures ,
Corporate Executives ,
Enforcement Actions ,
False Statements ,
Hang Seng China Enterprises Index (HSCEI) ,
Hang Seng Index (HSI) ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Internal Controls ,
Listing Applications ,
Listing Rules ,
Medical Devices ,
Medical Research ,
Mergers ,
Misappropriation ,
Misleading Statements ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Sanctions ,
Secondary Listings ,
SFC ,
Shareholders ,
Takeovers ,
Weighted Voting Rights (WVR)
This update provides an overview of recent developments that will affect preparation of annual results and annual reports for companies listed on The Stock Exchange of Hong Kong Limited (HKEX).
In particular, it covers...more
1/6/2020
/ Annual Reports ,
Biotechnology ,
Capital Requirements ,
Committee Meetings ,
Corporate Governance ,
Disclosure Requirements ,
Dual Class Share Structures ,
EBITDA ,
Enforcement Actions ,
Environmental Social & Governance (ESG) ,
Financial Statements ,
Foreign Corporations ,
Foreign Issuers ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Investment Funds ,
Listing Rules ,
Materiality ,
Non-GAAP Financial Measures ,
Publicly-Traded Companies ,
Secondary Listings ,
Shareholder Meetings ,
Trade Suspensions ,
Voting Rights
In the past year, nearly a dozen companies have taken advantage of new rules to list on the Stock Exchange of Hong Kong Limited (HKEx). On April 30, 2018, HKEx introduced a series of reforms to encourage the listing of...more
6/19/2019
/ Biotechnology ,
China ,
Corporate Executives ,
Dual Class Share Structures ,
EU ,
Food and Drug Administration (FDA) ,
HKEx ,
Hong Kong Stock Exchange ,
Innovative Technology ,
Listing Rules ,
Patent Registration ,
Popular ,
Publicly-Traded Companies ,
Research and Development ,
Shareholders ,
Threshold Requirements ,
United States ,
Weighted Voting Rights (WVR)
In April 2018, the Hong Kong Stock Exchange’s (HKEx) rule amendments permitting the listing of innovative, high-growth companies with dual-class share structures and pre-revenue biotech companies went into effect. The...more
1/23/2019
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
China ,
Dual Class Share Structures ,
Hong Kong ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Shanghai Stock Exchange ,
Shenzhen Stock Exchange (SZSE) ,
Stock Connect ,
Technology Sector ,
Trade Relations